Aurinia Pharmaceuticals (AUPH) Asset Utilization Ratio (2021 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Asset Utilization Ratio came in at 0.4 in Q1 2026, down 13.72% YoY from 0.47 in Q1 2025, and down 8.65% on a QoQ basis from 0.44 in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 6 years of Asset Utilization Ratio data on file, last reported at 0.4 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 13.72% year-over-year to 0.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.4 (down 13.72% YoY) and the FY2025 annual result came in at 0.43, up 1.57% from the prior year.
- Asset Utilization Ratio fell to 0.4 in Q1 2026, from 0.44 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.52 in Q2 2025 to a low of 0.13 in Q1 2022.
- A 5-year average of 0.36 and a median of 0.36 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 176.82% — and 2026, when it dropped 13.72%.
- Tracing AUPH's Asset Utilization Ratio over 5 years: stood at 0.28 in 2022, then gained by 13.86% to 0.32 in 2023, then soared by 34.34% to 0.43 in 2024, then advanced by 3.52% to 0.44 in 2025, then fell by 8.65% to 0.4 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.4 (Q1 2026), 0.44 (Q4 2025), and 0.52 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 0.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.41 |
| Mar 31, 2026 | 0.40 |
| Dec 31, 2025 | 0.44 |
| Sep 30, 2025 | 0.52 |
| Jun 30, 2025 | 0.52 |
| Mar 31, 2025 | 0.47 |
| Dec 31, 2024 | 0.43 |
| Sep 30, 2024 | 0.41 |
| Jun 30, 2024 | 0.40 |
| Mar 31, 2024 | 0.36 |
| Dec 31, 2023 | 0.32 |
| Sep 30, 2023 | 0.29 |
| Jun 30, 2023 | 0.32 |
| Mar 31, 2023 | 0.32 |
| Dec 31, 2022 | 0.28 |
| Sep 30, 2022 | 0.27 |
| Jun 30, 2022 | 0.18 |
| Mar 31, 2022 | 0.13 |
| Dec 31, 2021 | 0.10 |
| Sep 30, 2021 | 0.19 |